Since 2003, GEICO has belonged to the Gynecologic Cancer InterGroup (GCIG), an international platform that currently includes 18 cooperative groups from around the world dedicated to researching gynaecological cancer. The purpose of this platform is to promote and conduct high-quality clinical trials with the aim of improving the survival rate of women with gynaecological cancer, with five specific objectives:
- Encourage international cooperation
- Promote clinical research
- Conduct studies in rare tumours
- Stimulate evidence-based medicine
- Support educational activities
Joining and participating in the GICG has led to a significant advance in the research quality of the GEICO group, as from that moment it participated in some of the most significant international trials conducted in gynaecological oncology.
Furthermore, GEICO belongs to the ENGOT (European Network of Gynaecological Oncological Trial Groups), platform, which is a Pan-European network created by the European Society of Gynaecological Oncology (ESGO) to coordinate and promote clinical studies in patients with gynaecological cancer in Europe, prioritising academic studies, translational research, research in rare diseases, and industry-sponsored multi-national clinical trials to be conducted in Europe.
In addition, in 2010 GEICO joined the Gynecologic Oncology Group (GOG), a cooperative North American group who for years have been dedicated to gynaecological cancer research and who have developed many of the most significant clinical trials in this disease.